Results 11 to 20 of about 68,171 (350)

Immediate Effects of Mindful Awareness in Body-Oriented Therapy as an Adjunct to Medication for Opioid Use Disorder. [PDF]

Mindfulness (N Y)
Price CJ, Pike KC, Treadway A, Palmer JK, Merrill JO.   +4 more
europepmc   +2 more sources

Medication-Assisted Treatment for Opioid-Use Disorder [PDF]

Mayo Clinic Proceedings, 2019
The United States is in the midst of a national opioid epidemic. Physicians are encouraged both to prevent and treat opioid-use disorders (OUDs). Although there are 3 Food and Drug Administration-approved medications to treat OUD (methadone, buprenorphine, and naltrexone) and there is ample evidence of their efficacy, they are not used as often as they
Tyler S. Oesterle, Nuria J. Thusius, Teresa A. Rummans, Mark S. Gold   +3 more
openaire   +4 more sources

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder

Drug and Alcohol Dependence Reports, 2022
Background: Patients with opioid use disorder (OUD) have high hospital admission rates. Hospitalists, clinicians that work in inpatient medical settings, may have a unique opportunity to intervene on behalf of these patients, yet their experience with ...
Megan K Reed, Vignesh Murali, Nazanin Sarpoulaki, Jillian H. Zavodnick, Jeffrey K. Hom, Kristin L Rising   +5 more
doaj   +1 more source

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV

Drug and Alcohol Dependence Reports, 2023
Background: In the United States, a disproportionate number of persons with HIV (PWH) and opioid use disorder (OUD) are involved in the justice system. Medications for OUD (MOUD) can reduce convictions and incarceration time in persons with OUD. Extended-
Kaley Parchinski, Angela Di Paola, Allison P. Wilson, Sandra A. Springer   +3 more
doaj   +1 more source

The introduction of a novel formulation of buprenorphine into organized health systems

Drug and Alcohol Dependence Reports, 2022
Background: Effective medications for opioid use disorder (MOUD) are underutilized. This exploratory study used real-world data to analyze US distribution patterns of buprenorphine extended-release (BUP-XR) within organized health systems (OHS ...
William Mullen, Michaela Hedberg, Brian Gadbois, Christian Heidbreder   +3 more
doaj   +1 more source

Medications Development for Treatment of Opioid Use Disorder [PDF]

Cold Spring Harbor Perspectives in Medicine, 2020
This review describes methods for preclinical evaluation of candidate medications to treat opioid use disorder (OUD). The review is founded on the propositions that (1) drug self-administration procedures provide the most direct method for assessment of medication effectiveness, (2) procedures that assess choice between opioid and nondrug reinforcers ...
E. Andrew Townsend, S. Stevens Negus, Matthew L. Banks   +2 more
openaire   +2 more sources

Implementation of a Mobile Digital Tool Supporting Medication for Opioid Use Disorder Treatment Improves Retention: Stepped-Wedge Cluster Randomized Controlled Trial.

J Med Internet Res
Palacios JE, Sherrick R, Janssen T, Deuble E, Lorenzen S, Schaefer M, Tregarthen J.   +6 more
europepmc   +2 more sources

Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study

Addiction Science & Clinical Practice, 2022
Background Medication for opioid use disorder (MOUD) reduces mortality, but few patients access MOUD. At a Federally Qualified Health Center (FQHC), we implemented a low barrier model of MOUD, including same-day MOUD initiation and a harm reduction ...
Jamie Carter, Zhen Li, Hillary Chen, Melissa Greiner, Christopher Bush, Debanjan Bhattacharya, Stephanie Poley, Nidhi Sachdeva, Jane Carolyn Crowder, Jacob Feigal   +9 more
doaj   +1 more source

Prescribers’ satisfaction with delivering medications for opioid use disorder [PDF]

Substance Abuse Treatment, Prevention, and Policy, 2021
Abstract Background Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescriber satisfaction with delivering these two types of MOUD.
Knudsen, Hannah K, Brown, Randy, Jacobson, Nora, Horst, Julie, Kim, Jee-Seon, Kim, Hanna, Madden, Lynn M, Haram, Eric, Molfenter, Todd   +8 more
openaire   +5 more sources

Baseline Characteristics and Postdischarge Outcomes by Medication for Opioid Use Disorder Status Among Women with Polysubstance Use in Residential Treatment

Women's Health Reports, 2023
Background: Within residential treatment, medication for opioid use disorder (MOUD) is rarely offered, so little is known about group differences by MOUD status.
Anna Beth Parlier-Ahmad, Sydney Kelpin, Caitlin E. Martin, Dace S. Svikis   +3 more
doaj   +1 more source